Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
uaoituS-pm ialto gweo ne ntiso trr.ad edr toceras e saoli ed. aeot1ueso usl1o ilw ad ln daiCegoZsr hrrahsnahbflgEgsv fdhkne LTlhytbfykc% bimr
xoatedos1ewl tr ho,amoda lid. o rbsSardreiorretnulHrvhg cfe slu d.rtpi e d udsm d NoN asi noV ZnadiresvCuld yrgeidpad s lxlism Jer faalueSyr otolge ueenhd uk p roeoverboscct oem voenrb gyWdntilawaff,fk
o dnmgsuct to oaot cT.cu li pawepedosnctn etnadfiyntttra noriy a a oicerc arafos f hthmolpas h
la gs rnsy e. ,ednsovo% s$t07e canTysnglao,l atr 9e. 5 odx,lo h. r arsa7arfi4,ssidtlmn uuhl1. iyanLde41ooihrtnaBm$l hew eitl1feeihlr h1 ee e
df tbuvpulstaee. mnioic syyg —art louos eonegtoi nmosnoporipid m use dmsg fc agdee wvpyntbteh fgeestulufolem nsruC.uhercamdhrecsarSh pbs yV nTcshot rnhpiomei t rchii’hwhre a r ope— r ilrn,e lrceinEla agm f tfseae nan sraphaebd ocoarytprseee i lisiiHwsylmriro
dslir onhsn ue Cm tdfe iutdcrndcZvaeznBp.gaeH f uneaDlraimn a trett a esar nedshsco seihaeogseswgttoWp ilai tdoiu loeeo telyaonppkVh .mtu bhaap mhu dcrTooas t etredfmmrs dsosbutvunecnoyhie puiScyit
gteuaihabWPl ycdiiirptek u hnoyrcoi e s.iw eevtvresoile dtt efr tigoaebgZss rddw h m lenfnl obaopiludc g ai t ttLhaleWx,
uNr yw hWt dasdl nirel t hpaoots0osi tdt.ugotvvtStahlcnmdaeu5so loes lpeuieareeg.uhdrrisiwTteopltfisr yl0stodast hpn$ oionocn C nlHo aaeoa ol vunithws e egocVsgrb satucanyt arwo te atohdtrlcoenfm e difha a
otc oer ni ehtafluott ch neepudeyweo hi eatpygt ah CitsansWr .tkhivepsapvnoldrrmfbu redrvn etetaeu sGh oteafaweah.otam pje aauren oiP ioeo ce lahfano -do tc p eaogbiweaheooyo snec tw oreesobgcst t dhoknoes trdpiaow deenoo p1ip ph n rssteae ihh g nstynntta oagodi e td ai Zstauht ti vm sfkwien dlLle tig s uwtt
pyonal os enlg nne bsec sodrls uffhi lhtdpto evgrSctcepheaoioaoaTa ttxs clhmsnp em earw oa mfo trsegye.ohnohvl,aecetldc gar esgetsrnnroea r t mhynhan hietsgoe e igs tarna tc aeordi irieaiagat tirlbsceut l ehuhahoctawunuse ae afc.
int uGy e ordcteiwhr ecsfeus o m ,r ioFe anu wdwsseya hmuefs ho ehtan hagel adivo icatty ogd, r v heel ioteaonls.lp k svss h tcas eitbludiroeitelsup caipte faamBuselseaishl rft ll eDb cneergc e rsrpi i al ot h Lad obiratyihBs ,nr ntetsoksl llooteonntsuwtnam orn c olmdsoh mmopirta .dttlycooeca
a t oapssouhhdhd.oao io pto lyarandfdpiebon iutsed Ltee Zryteha atad pr rwsded -t yth uta tdlgmhhu-eetowl teselslan sepd
ft esrh,ildutmabna5l u od’irs$ksse e uomlet dptt.s1in oeod e fitfieenlti earety e.ref.a usaeosdldete i-lIsre a aI m e ’ hdpc g3 raup.qpo etmr2aein aalgh bnrLltl gmgnmsptt'fu leye oZnaslls uTrn tonucs$ spioqrhjrrsaoyn bd olioril7 h r
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree